Raymond James Financial’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$580M Sell
1,602,419
-17,934
-1% -$6.14M 0.16% 107
2026
Q1
$570M Sell
1,620,353
-82,397
-5% -$29.4M 0.18% 99
2025
Q4
$557M Sell
1,702,750
-43,766
-3% -$13.9M 0.17% 101
2025
Q3
$493M Buy
1,746,516
+20,888
+1% +$6.06M 0.16% 106
2025
Q2
$482M Buy
1,725,628
+49,283
+3% +$14M 0.17% 105
2025
Q1
$522M Buy
1,676,345
+134,321
+9% +$39.7M 0.2% 96
2024
Q4
$402M Buy
+1,542,024
New +$458M 0.15% 117

Other funds holding AMGN

Raymond James Financial's AMGN Position: Q2 2026 in Review

Raymond James Financial reduced its Amgen (AMGN) stake by 1.1% in Q2 2026, selling an estimated $6.14M and leaving 1,602,419 shares worth $580M. The position accounts for 0.16% of the portfolio, ranked #107.

Raymond James Financial first reported a position in AMGN in Q4 2024 and has held it in 7 quarters since. 3,164 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Raymond James Financial held 1,602,419 shares of Amgen worth $580M as of Q2 2026.
  • Raymond James Financial sold 17,934 Amgen shares in Q2 2026, an estimated $6.14M.
  • Amgen made up 0.16% of Raymond James Financial's portfolio in Q2 2026, its #107 holding.
  • Raymond James Financial first reported a position in Amgen in Q4 2024 and has held it in 7 quarters since.
  • 3,164 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.